What are the Class IC antiarrhythmic agents, their dosing regimens, and clinical indications?

Class IC Antiarrhythmic Agents

Class IC antiarrhythmics include flecainide and propafenone, which are sodium channel blockers effective for rhythm control in atrial fibrillation and supraventricular arrhythmias, but are contraindicated in patients with coronary artery disease, prior myocardial infarction, heart failure (LVEF <40%), or significant structural heart disease due to increased mortality risk. 1, 2, 3

Specific Agents and Dosing

Flecainide

• Oral dosing: 50-200 mg every 12 hours 2
• Immediate release: 150-300 mg every 8 hours (alternative regimen) 2
• Elimination half-life: 12-27 hours, allowing twice-daily dosing 4

Propafenone

• Immediate release: 150-300 mg every 8 hours 2
• Extended release: 225-425 mg every 12 hours 2
• "Pill-in-the-pocket": Single 600 mg oral dose for acute cardioversion 5, 1
• Note: Propafenone has both Class IC and Class II (beta-blocking) effects 6

Clinical Indications

Appropriate Use (Class I/IIa Recommendations)

• Cardioversion of atrial fibrillation/flutter in structurally normal hearts 2, 3
• Maintenance of sinus rhythm in patients without structural heart disease 1, 3
• Supraventricular arrhythmias including AVNRT in patients without structural disease 7
• Idiopathic ventricular arrhythmias in the absence of structural heart disease 8, 9

"Pill-in-the-Pocket" Strategy

For self-administration of acute AF episodes 5, 1:

1. Must first prove safe during monitored in-hospital trial
2. Requires pre-treatment with AV nodal blocking agent (beta-blocker or non-dihydropyridine calcium channel blocker) given at least 30 minutes before Class IC drug
3. Only for patients with structurally normal hearts
4. Typical dose: propafenone 600 mg or flecainide 300 mg

Absolute Contraindications

Do NOT use Class IC agents in patients with: 10, 2, 3, 11

• Coronary artery disease or prior myocardial infarction
• Heart failure or LVEF <40%
• Significant left ventricular hypertrophy
• Second- or third-degree AV block without pacemaker
• Left bundle branch block or bifascicular block
• Severe renal impairment (CrCl <35 mL/min)
• Severe hepatic impairment
• Brugada syndrome

Critical Safety Considerations

Proarrhythmic Risk

The landmark finding from the Cardiac Arrhythmia Suppression Trial demonstrated increased mortality when Class IC drugs were used in patients with ventricular scarring from myocardial infarction 10. This occurs through facilitation of reentrant ventricular tachycardia via decreased conduction and heterogeneous action potential prolongation 10.

Pre-Treatment Requirements

Before initiating Class IC agents: 3

1. Perform formal ischemia assessment (stress test) in patients >50 years or with atherosclerotic risk factors
2. Obtain baseline ECG
3. Ensure normal renal and hepatic function
4. Initiate AV nodal blocking agent (beta-blocker or non-dihydropyridine calcium channel blocker) to prevent 1:1 atrial flutter conduction 3

Monitoring During Treatment

• Repeat ECG after initiation to assess for PR and QRS prolongation 3
• QRS widening >25% from baseline increases proarrhythmia risk 3
• Annual assessment for CAD symptoms with stress testing if symptoms develop 3

Special Populations

Congenital Heart Disease

Class IC drugs carry uncertain but potentially significant proarrhythmic risk in adults with congenital heart disease due to incisional scars, baffles, conduits, and myocardial fibrosis 10. In one study of 579 young patients (24% with CHD), proarrhythmic events occurred in 7.4-7.5%, with cardiac arrests and deaths predominantly in those with underlying heart disease 10. Avoid in CHD patients with coronary disease or systolic dysfunction 10.

Emerging Evidence

Recent data suggest Class IC agents may be safe in chronic stable coronary disease without prior MI or residual ischemia, and in select structural heart disease like arrhythmogenic right ventricular cardiomyopathy and tachycardia-induced cardiomyopathy 8, 9. However, guidelines have not yet incorporated these findings into formal recommendations.

Drug Interactions

Flecainide

• Metabolized by CYP2D6 (genetically absent in 7-10% of population) 2
• CYP2D6 inhibitors (quinidine, fluoxetine, tricyclics) increase levels
• Dual impairment with renal dysfunction can significantly increase plasma concentrations

Propafenone

• Metabolized by CYP2D6 2
• Poor metabolizers experience increased beta-blockade 2
• Inhibits P-glycoprotein: increases digoxin levels 2
• Inhibits CYP2C9: increases warfarin effect (INR increases ~25%) 2

Key Pitfall to Avoid

The most dangerous error is using Class IC agents in patients with structural heart disease or coronary artery disease. Always exclude ischemic heart disease before initiation, and never use these drugs in patients with reduced ejection fraction or prior myocardial infarction, as this directly increases mortality risk 10, 1, 3.